ONECUT2 and hepatocellular carcinoma: We found that both PD173074 and ETC-1002 inhibited ONECUT2-mediated HCC metastasis when used alone, but the inhibitory effect was more obvious when used in combination, providing a potential therapeutic strategy for ONECUT2-driven HCC metastasis.